You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for metformin hydrochloride; rosiglitazone maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00131664 ↗ Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) Completed GlaxoSmithKline Phase 3 2005-09-01 The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes Association guidelines glucose control, based on the A1C measurement, needs to be achieved within a 6-12 month period of time after the initial diagnosis of type 2 diabetes. The guidelines on the use of antihyperglycemic agents identify the potential benefits of sub-maximal oral combination therapy in order to achieve more rapid and improved glycemic control compared with higher dose monotherapy. Furthermore, many patients on prolonged oral antihyperglycemic monotherapy who then start on combination therapy may not achieve the required target glycemic control. Indeed early initiation of combination therapies may be necessary to achieve and maintain glycemic targets because of the progressive deterioration of pancreatic β cell function and glycemic control.
NCT00131664 ↗ Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) Completed Canadian Heart Research Centre Phase 3 2005-09-01 The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes Association guidelines glucose control, based on the A1C measurement, needs to be achieved within a 6-12 month period of time after the initial diagnosis of type 2 diabetes. The guidelines on the use of antihyperglycemic agents identify the potential benefits of sub-maximal oral combination therapy in order to achieve more rapid and improved glycemic control compared with higher dose monotherapy. Furthermore, many patients on prolonged oral antihyperglycemic monotherapy who then start on combination therapy may not achieve the required target glycemic control. Indeed early initiation of combination therapies may be necessary to achieve and maintain glycemic targets because of the progressive deterioration of pancreatic β cell function and glycemic control.
NCT00150410 ↗ Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose Completed Sanofi Phase 3 2003-01-01 - Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia, a Food and Drug Administration (FDA) approved drug. - Whether a combination of two therapies - metformin plus Exubera controls your diabetes at least as much as a as a triple combination therapy of metformin and a sulfonylurea plus Avandia.
NCT00150410 ↗ Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose Completed Pfizer Phase 3 2003-01-01 - Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia, a Food and Drug Administration (FDA) approved drug. - Whether a combination of two therapies - metformin plus Exubera controls your diabetes at least as much as a as a triple combination therapy of metformin and a sulfonylurea plus Avandia.
NCT00359112 ↗ AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes Completed GlaxoSmithKline Phase 3 2004-02-01 This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.
NCT00484419 ↗ Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin Completed Daiichi Sankyo Inc. Phase 3 2007-05-01 A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.
NCT00484419 ↗ Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin Completed Daiichi Sankyo, Inc. Phase 3 2007-05-01 A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for metformin hydrochloride; rosiglitazone maleate

Condition Name

Condition Name for metformin hydrochloride; rosiglitazone maleate
Intervention Trials
Type 2 Diabetes 1
Type 2 Diabetes Mellitus 1
Diabetes Mellitus 1
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for metformin hydrochloride; rosiglitazone maleate
Intervention Trials
Diabetes Mellitus 5
Diabetes Mellitus, Type 2 4
Hyperlipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for metformin hydrochloride; rosiglitazone maleate

Trials by Country

Trials by Country for metformin hydrochloride; rosiglitazone maleate
Location Trials
United States 51
Mexico 10
Germany 10
Canada 5
Italy 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for metformin hydrochloride; rosiglitazone maleate
Location Trials
Maryland 2
Indiana 2
Florida 2
California 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for metformin hydrochloride; rosiglitazone maleate

Clinical Trial Phase

Clinical Trial Phase for metformin hydrochloride; rosiglitazone maleate
Clinical Trial Phase Trials
Phase 3 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for metformin hydrochloride; rosiglitazone maleate
Clinical Trial Phase Trials
Completed 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for metformin hydrochloride; rosiglitazone maleate

Sponsor Name

Sponsor Name for metformin hydrochloride; rosiglitazone maleate
Sponsor Trials
GlaxoSmithKline 3
Daiichi Sankyo, Inc. 1
Canadian Heart Research Centre 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for metformin hydrochloride; rosiglitazone maleate
Sponsor Trials
Industry 7
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.